Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 110

1.

Barking up the wrong genome--we are not alone.

Li-Wan-Po A, Farndon P.

J Clin Pharm Ther. 2011 Apr;36(2):125-7. doi: 10.1111/j.1365-2710.2010.01240.x. Epub 2011 Jan 16.

PMID:
21366639
[PubMed - indexed for MEDLINE]
2.

Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT) 1A family members and its role in patient response to irinotecan.

Nagar S, Blanchard RL.

Drug Metab Rev. 2006;38(3):393-409. Review.

PMID:
16877259
[PubMed - indexed for MEDLINE]
3.

Pharmacogenetics of irinotecan: a promoter polymorphism of UGT1A1 gene and severe adverse reactions to irinotecan.

Ando M, Hasegawa Y, Ando Y.

Invest New Drugs. 2005 Dec;23(6):539-45.

PMID:
16267624
[PubMed - indexed for MEDLINE]
4.

Severe irinotecan-induced toxicities in a patient with uridine diphosphate glucuronosyltransferase 1A1 polymorphism.

Mehra R, Murren J, Chung G, Smith B, Psyrri A.

Clin Colorectal Cancer. 2005 May;5(1):61-4.

PMID:
15929808
[PubMed - indexed for MEDLINE]
5.

Insights, challenges, and future directions in irinogenetics.

Kim TW, Innocenti F.

Ther Drug Monit. 2007 Jun;29(3):265-70. Review.

PMID:
17529881
[PubMed - indexed for MEDLINE]
6.

Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer.

Araki K, Fujita K, Ando Y, Nagashima F, Yamamoto W, Endo H, Miya T, Kodama K, Narabayashi M, Sasaki Y.

Cancer Sci. 2006 Nov;97(11):1255-9. Epub 2006 Sep 12.

PMID:
16965601
[PubMed - indexed for MEDLINE]
7.

UGT1AI*6 and UGT1A1*27 for individualized irinotecan chemotherapy.

Ando Y, Fujita K, Sasaki Y, Hasegawa Y.

Curr Opin Mol Ther. 2007 Jun;9(3):258-62. Review.

PMID:
17608024
[PubMed - indexed for MEDLINE]
8.

Pharmacogenetic approach for cancer treatment-tailored medicine in practice.

Hasegawa Y, Ando Y, Ando M, Hashimoto N, Imaizumi K, Shimokata K.

Ann N Y Acad Sci. 2006 Nov;1086:223-32. Review.

PMID:
17185519
[PubMed - indexed for MEDLINE]
9.

Polymorphisms of the UDP-glucuronosyl transferase 1A genes are associated with adverse events in cancer patients receiving irinotecan-based chemotherapy.

Inoue K, Sonobe M, Kawamura Y, Etoh T, Takagi M, Matsumura T, Kikuyama M, Kimura M, Minami S, Utsuki H, Yamazaki T, Suzuki T, Tsuji D, Hayashi H, Itoh K.

Tohoku J Exp Med. 2013;229(2):107-14.

PMID:
23303296
[PubMed - indexed for MEDLINE]
Free Article
10.

Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28.

Minami H, Sai K, Saeki M, Saito Y, Ozawa S, Suzuki K, Kaniwa N, Sawada J, Hamaguchi T, Yamamoto N, Shirao K, Yamada Y, Ohmatsu H, Kubota K, Yoshida T, Ohtsu A, Saijo N.

Pharmacogenet Genomics. 2007 Jul;17(7):497-504.

PMID:
17558305
[PubMed - indexed for MEDLINE]
11.

Irinotecan treatment in cancer patients with UGT1A1 polymorphisms.

Innocenti F, Ratain MJ.

Oncology (Williston Park). 2003 May;17(5 Suppl 5):52-5. Review.

PMID:
12800608
[PubMed - indexed for MEDLINE]
12.

Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics: to test or not to test, that is the question.

Deeken JF, Slack R, Marshall JL.

Cancer. 2008 Oct 1;113(7):1502-10. doi: 10.1002/cncr.23777. Review.

PMID:
18720361
[PubMed - indexed for MEDLINE]
Free Article
13.

UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer.

Marcuello E, Altés A, Menoyo A, Del Rio E, Gómez-Pardo M, Baiget M.

Br J Cancer. 2004 Aug 16;91(4):678-82.

PMID:
15280927
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Pharmacogenetics of irinotecan disposition and toxicity: a review.

Fujita K, Sparreboom A.

Curr Clin Pharmacol. 2010 Aug;5(3):209-17. Review.

PMID:
20406168
[PubMed - indexed for MEDLINE]
15.

Pharmacogenetic pathway analysis of irinotecan.

Rosner GL, Panetta JC, Innocenti F, Ratain MJ.

Clin Pharmacol Ther. 2008 Sep;84(3):393-402. doi: 10.1038/clpt.2008.63. Epub 2008 Apr 16.

PMID:
18418374
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

UGT1A1*28 and other UGT1A polymorphisms as determinants of irinotecan toxicity.

Biason P, Masier S, Toffoli G.

J Chemother. 2008 Apr;20(2):158-65. Review.

PMID:
18467239
[PubMed - indexed for MEDLINE]
17.

Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study.

de Jong FA, Kehrer DF, Mathijssen RH, Creemers GJ, de Bruijn P, van Schaik RH, Planting AS, van der Gaast A, Eskens FA, Janssen JT, Ruit JB, Verweij J, Sparreboom A, de Jonge MJ.

Oncologist. 2006 Sep;11(8):944-54.

PMID:
16951398
[PubMed - indexed for MEDLINE]
Free Article
18.

Increased frequency of uridine diphosphate glucuronosyltransferase 1A1 7/7 in patients experiencing severe irinotecan-induced toxicities.

Fakih MG, Ross ME, Starostik P.

Clin Colorectal Cancer. 2007 Jul;6(8):583-7.

PMID:
17681105
[PubMed - indexed for MEDLINE]
19.

Pharmacogenetics of irinotecan.

Toffoli G, Cecchin E, Corona G, Boiocchi M.

Curr Med Chem Anticancer Agents. 2003 May;3(3):225-37. Review.

PMID:
12769780
[PubMed - indexed for MEDLINE]
20.

[Role of UGT1A1*28 and UGT1A1*6 for irinotecan-induced adverse drug reaction].

Onoue M, Inui K.

Gan To Kagaku Ryoho. 2008 Jul;35(7):1080-5. Japanese.

PMID:
18633245
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk